Clinical Trial

First-In-Human Study of KHN922 for Injection

Name: First-In-Human Study of KHN922 for Injection — clinical trial record (NCT07514975)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-03-31.

Trial Details

NCT Number	NCT07514975
Lead Sponsor	Chengdu Kanghong Biotech Co., Ltd.
Conditions	Advanced Solid Tumors Cancer
Enrollment	276 participants
Start Date	2026-04
Primary Completion	2028-04 (estimated)
Study Completion	2029-04 (estimated)
Updated on ClinicalTrials.gov	2026-04-09